Yes, metformin is eliminated primarily unchanged through the kidneys.
Metformin is excreted unchanged in the urine via renal filtration and tubular secretion, with approximately 90% of the absorbed drug eliminated through the renal route within 24 hours. 1 The drug undergoes no hepatic metabolism and no metabolites have been identified in humans 1. Renal clearance is approximately 3.5 times greater than creatinine clearance, indicating that active tubular secretion is the major route of elimination 1.
Key Pharmacokinetic Details
Elimination characteristics:
- Plasma elimination half-life: approximately 6.2 hours after oral administration
- Blood elimination half-life: approximately 17.6 hours (suggesting erythrocyte distribution) 1
- No biliary excretion occurs 1
- The drug is negligibly bound to plasma proteins 1
Clinical Implications of Renal Elimination
Because metformin depends entirely on kidney function for elimination, renal impairment directly prolongs the drug's half-life and decreases clearance 1. This creates the primary safety concern with metformin use:
In patients with decreased kidney function:
- Metformin clearance decreases by approximately 75% when eGFR falls to 60 mL/min/1.73 m² 2
- Plasma and blood half-life become prolonged 1
- Risk of drug accumulation increases, potentially leading to lactic acidosis 3
Current Dosing Guidelines Based on Renal Function
The most recent consensus recommendations 4, 3 establish clear eGFR-based thresholds:
- eGFR ≥60 mL/min/1.73 m²: Continue standard dosing; monitor eGFR at least annually
- eGFR 45-59 mL/min/1.73 m²: Continue same dose, but consider reduction in patients with comorbidities increasing lactic acidosis risk (hypoperfusion, hypoxemia); increase monitoring frequency to every 3-6 months 4, 3
- eGFR 30-44 mL/min/1.73 m²: Reduce dose to maximum 1000 mg daily 4, 3
- eGFR <30 mL/min/1.73 m²: Contraindicated; discontinue metformin 4, 5, 1
Important Clinical Caveats
Temporary discontinuation is essential during acute illness that may compromise renal function 2, 6:
- Before iodinated contrast procedures (when eGFR 30-60 mL/min/1.73 m²) 5
- During serious intercurrent illness increasing acute kidney injury risk
- In situations causing hypoperfusion or hypoxemia
The risk of metformin-associated lactic acidosis remains very low when these guidelines are followed 2, 6. Most cases occur when acute kidney injury develops in patients already on metformin, further reducing drug clearance 3.
The FDA revised its guidance in 2016 to reflect this safety profile, expanding metformin use to patients with eGFR ≥30 mL/min/1.73 m² (previously contraindicated at serum creatinine >1.5 mg/dL in men or >1.4 mg/dL in women) 5, 3.